Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

FDA Approved Xalkori for Young Patients with Anaplastic Large-Cell Lymphoma and ALK Mutation

February 2021 Vol 7 No 1

In January 2021, the FDA approved Xalkori (crizotinib; from Pfizer), an oral ALK inhibitor, for the treatment of young patients aged 1 to 21 years who are diagnosed with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) and ALK mutation.

Xalkori was previously approved for patients with metastatic non–small-lung cancer and ALK or ROS1 mutation.

This new indication for the targeted therapy Xalkori was based on the results of a single-arm clinical trial in 26 patients aged 1 to 21 years who had been diagnosed with relapsed or refractory ALCL and ALK mutation. The study did not include older people with this diagnosis. All the patients had previously received at least 1 systemic treatment for this diagnosis.

In the study, 20 patients received treatment with Xalkori at a dose of 280 mg/m2 twice daily and the other 6 patients received Xalkori at a dose of 165 mg/m2 twice daily, until their disease progressed or until they had unacceptable side effects. The patients were allowed to discontinue treatment with Xalkori therapy so they could have a stem-cell transplant if they wanted.

Of the 26 patients in the study, 23 (88%) patients had a response to Xalkori therapy; furthermore, 81% of these patients had a complete remission (no sign of disease). Among the 23 patients who had a response to therapy, 39% had a response lasting 6 months or more, and 22% had a response lasting 12 months or more.

The most common side effects were diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, fever, abdominal pain, cough, and pruritus.

Serious side effects, including neutropenia and infection, occurred in 35% of the patients.

Recommended For You